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2Abstract
A growing body of evidence indicates that the progression of cancer can be viewed as an eco-
evolutionary process. Under this perspective, we present here a space- and phenotype-structured
model of selection dynamics between cancer cells within a solid tumour. In the framework of
this model, we combine formal analyses with numerical simulations to investigate in silico the
role played by the spatial distribution of abiotic components of the tumour microenvironment
in mediating phenotypic selection of cancer cells. Numerical simulations are performed both on
the 3D geometry of an in silico multicellular tumour spheroid and on the 3D geometry of an
in vivo human hepatic tumour, which was imaged using computerised tomography. The results
obtained show that inhomogeneities in the spatial distribution of oxygen, currently observed
in solid tumours, can promote the creation of distinct local niches and lead to the selection of
different phenotypic variants within the same tumour. This process fosters the emergence of
stable phenotypic heterogeneity and supports the presence of hypoxic cells resistant to cytotoxic
therapy prior to treatment. Our theoretical results demonstrate the importance of integrating
spatial data with ecological principles when evaluating the therapeutic response of solid tumours.
Introduction
Significant progress in understanding the mechanisms behind cancer development and progres-
sion has been achieved in recent years by using molecular-based sequencing techniques [1–7].
Despite this growing knowledge, we are far from a complete understanding of the principles that
govern the emergence of intratumour heterogeneity. This poses a major obstacle to successful
cancer chemotherapy and management of disease relapse [8–10].
A novel perspective on cancer therapeutics can be obtained from the accumulating evidence
indicating that the progression of solid tumours is, in essence, an eco-evolutionary process [11–
13]. Firstly, new phenotypic variants emerge in the tumour via mutations and epimutations.
Afterwards, these variants are subject to natural selection and they proliferate and die under
3the selective pressures of the tumour microenvironment. From this evolutionary viewpoint,
spatial variations in the distribution of abiotic components of the tumour microenvironment
(e.g., nutrients and therapeutic agents) may lead to the creation of distinct local niches and
thus provide ecological opportunities for diversification [14–17].
To explore in silico the validity of such an ecological argument linking heterogeneity in
the distribution of abiotic components of the tumour microenvironment to the development
and maintenance of phenotypic heterogeneity between cancer cells, we present here a space-
and phenotype-structured model of selection dynamics in a solid tumour. Our model consists
of an integro-differential equation (IDE) for the spatiotemporal evolution of the phenotypic
distribution of cancer cells [18–21] coupled to a system of partial differential equations (PDEs)
for the dynamics of abiotic factors [22–24].
Recent studies based on various mathematical modelling approaches support related hy-
potheses concerning the emergence of intratumour heterogeneity. For instance, Fu et al. [25]
have proposed a model based on a multi-type stochastic branching process describing growth
of cancer cells in multiple spatial compartments characterised by different environmental con-
ditions. Further, Lorz et al. [26] have developed an IDE model of phenotypic selection in a
radially symmetric tumour spheroid viewed as a population structured by a phenotypic trait
and a 1D spatial variable. More recently, Lloyd et al. [27] have considered an evolutionary game
theory model of habitat heterogeneity where the tumour is composed of two compartments – the
tumour core and the tumour edge – treated as two different habitats. Although these studies
provide a valuable proof of concept for the hypothesis that spatial gradients of abiotic factors
cause the selection of different phenotypic properties in distinct regions within the same solid
tumour, they are based on mathematical models that rely on rather strong simplifying modelling
assumptions. On the contrary, our mathematical model requires no specific assumptions on the
tumour geometry, and its parameters can be linked to experimentally measurable quantities.
For these reasons, the model presented here offers a more flexible and realistic mathematical
framework for studying phenotypic selection between cancer cells within solid tumours.
4In this paper, integrating the results of formal analyses with numerical simulations, we show
that inhomogeneities in the spatial distribution of oxygen, which are recurrently observed in solid
tumours, can promote the creation of distinct local niches and lead to the selection of different
phenotypic variants within the same tumour. This process fosters the emergence of stable phe-
notypic heterogeneity and supports the presence of hypoxic cells resistant to cytotoxic therapy
prior to treatment. Moreover, our theoretical results reveal how intratumour heterogeneity can
reduce the efficacy of cytotoxic drugs, leading to poor treatment outcomes, and demonstrate the
importance of integrating spatial data with ecological principles when evaluating the therapeutic
response of solid tumours.
Model description
We identify the tumour geometry with a spatial domain Ω ⊂ R3. At time t and for each point
x ∈ Ω, the function n(t,x, y) ≥ 0 describes the phenotypic distribution of cells. The vector
x denotes the position in the tumour and the continuous scalar variable y ∈ [0, 1] represents
the normalised expression level of a hypoxia-responsive gene [28, 29]. Cells within the tumour
proliferate and die due to competition for limited space. Moreover, a cytotoxic drug can be
administered which acts by increasing the death rate of cells. We assume increasing values of
the phenotypic state y to be correlated with a progressive switch towards a hypoxic phenotype,
which, in turn, implies a progressive reduction in the proliferation rate [27, 30]. Additionally,
given that cytotoxic agents target mostly rapidly proliferating cells, we assume higher values of
the phenotypic state y correspond to higher levels of resistance to the cytotoxic drug [31,32].
Given the local population density of cells in the tumour n(t,x, y), we define the local density
of cells ρ(t,x) and the total number of cells N(t) as follows
ρ(t,x) =
∫ 1
0
n(t,x, y) dy, N(t) =
∫
Ω
ρ(t,x) dx. (1)
5The mean cell phenotypic state at position x and time t can be computed as
µ(t,x) =
1
ρ(t,x)
∫ 1
0
y n(t,x, y) dy. (2)
Finally, we introduce the functions s(t,x) ≥ 0 and c(t,x) ≥ 0 to model the local concentration
of oxygen and cytotoxic drug at position x and time t, respectively.
Dynamics of cancer cells
The dynamics of the local population density n(t,x, y) is governed by the following nonlinear
IDE
∂n
∂t
(t,x, y) = R
(
y, ρ(t,x), s(t,x), c(t,x)
)
n(t,x, y). (3)
In (3), the function R
(
y, ρ(t,x), s(t,x), c(t,x)
)
represents the fitness of cells with phenotypic
state y at position x and time t, given the local environmental conditions . These are determined
by the local cell density ρ(t,x) as well as by the concentrations of abiotic factors s(t,x) and
c(t,x). Throughout the paper, we define the fitness landscape of the tumour as
R
(
y, ρ(t,x), s(t,x), c(t,x)
)
= p(y, s(t,x))− k(y, c(t,x))− dρ(t,x). (4)
The definition given by (4) relies on the idea that a higher cell density ρ(t,x) at position x
corresponds to a more intense competition for space. We assume cells located at position x
die with rate dρ(t,x), where the parameter d > 0 represents the death rate due to intratumour
competition between cells. The function k(y, c) ≥ 0 models the additional death rate due to the
cytotoxic drug. Since increasing values of the phenotypic state y correspond to higher levels of
cytotoxic-drug resistance, we assume the function k to be decreasing in y. Moreover, since the
death rate increases with higher drug concentrations, we assume the function k to be increasing
in the drug dose c. The function p(y, s) ≥ 0 represents the cell proliferation rate, which we
6define as
p(y, s(t,x)) = f(y) + r(y, s(t,x)). (5)
The function f(y) is the proliferation rate under hypoxic conditions and is, therefore, an increas-
ing function of the phenotypic state y [33]. The function r(y, s) is decreasing in the phenotypic
state y and increasing in the oxygen concentration s, since it models the rate of cell proliferation
in oxygenated environments [14]. In this paper we consider
f(y) = ζ
[
1− (1− y)2
]
, (6)
r(y, s(t,x)) = γs
s(t,x)
αs + s(t,x)
(
1− y2), (7)
k(y, c(t,x)) = γc
c(t,x)
αc + c(t,x)
(1− y)2. (8)
These definitions satisfy the generic properties listed above and ensure analytical tractability
of the model. The definitions (7) and (8) rely on the assumption that the consumption of
oxygen and cytotoxic drug is governed by Michaelis-Menten kinetics with constants αs > 0 and
αc > 0, respectively [22, 24]. The parameter γc > 0 is the maximum cell death rate induced
by the cytotoxic drug. The parameters ζ > 0 and γs > 0 represent the maximum proliferation
rate under hypoxic conditions and in oxygenated environments, respectively. Previous empirical
studies suggest that cancer cells inhabiting hypoxic regions in solid tumours proliferate more
slowly than cells populating oxygenated regions [27, 31, 34]. In our modelling framework this
observation is captured by the additional assumption ζ  γs.
Dynamics of abiotic factors
The abiotic factors (i.e., oxygen and cytotoxic drug) diffuse in space, decay and are consumed
by cells. We note that the dynamics of abiotic factors is faster than cellular proliferation and
death [35,36]. From a mathematical viewpoint, this means that we can assume oxygen and the
cytotoxic drug to be in quasi-stationary equilibrium. Under these assumptions, the dynamics of
7the functions s(t,x) and c(t,x) are described by the following elliptic PDEs that are coupled to
the IDE (3)
βs∆s(t,x) = ηs
∫ 1
0
r
(
y, s(t,x)
)
n(t,x, y) dy + λss(t,x), (9)
βc∆c(t,x) = ηc
∫ 1
0
k
(
y, c(t,x)
)
n(t,x, y) dy + λcc(t,x). (10)
In the above equations, the parameters βs > 0 and βc > 0 represent the diffusion constants of
oxygen and the cytotoxic drug. The parameters ηs > 0 and ηc > 0 are the scaling factors for
the consumption rate of abiotic factors by cells in the tumour. The parameters λs > 0 and
λc > 0 represent the decay rates of oxygen and the cytotoxic drug. Focussing on the biological
scenario in which the concentrations of abiotic factors in the medium surrounding the tumour
are constant in time, we make use of the following boundary conditions for (9) and (10)
s(·,x) = S(x) and c(·,x) = C(x), x ∈ ∂Ω. (11)
The functions S(x) and C(x) model the concentrations of oxygen and cytotoxic drug on the
tumour boundary ∂Ω.
Table 1. Parameter values used to perform numerical simulations
Parameter Biological meaning Value Reference
αc Michaelis-Menten constant of cytotoxic drug 2× 10−6 g cm−3 [22, 37]
αs Michaelis-Menten constant of oxygen 1.5× 10−7 g cm−3 [38]
βc Diffusion coefficient of cytotoxic drug 5× 10−6 cm2 s−1 [22, 39]
βs Diffusion coefficient of oxygen 2× 10−5 cm2 s−1 [40]
γc Maximum cell death rate induced by cytotoxic drug 1.8× 10−4 s−1 [22, 37]
γs Maximum cell proliferation rate in oxygenated environments 1× 10−5 s−1 [24, 38]
ζ Maximum cell proliferation rate under hypoxic conditions 1× 10−6 s−1 [30]
d Rate of cell death due to competition for space 2× 10−14 cm3 s−1 cell−1 [41]
ηc Scaling factor for cell consumption of cytotoxic drug 4× 10−12 g cell−1 [22, 37]
ηs Scaling factor for cell consumption of oxygen 2× 10−12 g cell−1 [38]
λc Decay rate of cytotoxic drug 0.1 s−1 [42]
λs Decay rate of oxygen 0.3 s−1 [23]
ρ0 Reference value for the local cell density 109 cells cm−3 [41]
s0 Reference value for the local concentration of oxygen 6.3996× 10−7 g cm−3 [43]
c0 Reference value for the local concentration of cytotoxic drug 10−5 g cm−3 [22]
8Formal analysis of phenotypic selection
To obtain an analytical description of phenotypic selection, we assume that all possible pheno-
typic variants exist in the tumour at time t = 0, i.e., we set n(0,x, y) > 0 for all x ∈ Ω and
all y ∈ [0, 1]. Additionally, we assume that the number of cells in the tumour is bounded above
and below. Given this scenario, for every position x ∈ Ω, the local cell density at equilibrium
ρ(x) satisfies the following condition
max
y∈[0,1]
R
(
y, ρ(x), s(x), c(x)
)
= 0,
where s(x) and c(x) stand for the steady-state distributions of oxygen and cytotoxic drug,
respectively. Since the fitness landscape R is a monotonically decreasing function of the local
number of cells, for every x, there is a unique value of ρ(x) that satisfies the above relation.
Moreover, given Eqs. (6)-(8), the fitness landscape R is a strictly concave function of y for all
values of ρ(x), s(x) and c(x). This implies that, for all values of x, there exists one single
phenotypic state y(x) which maximises the fitness landscape R at equilibrium. Therefore, for
each x there is a unique dominant phenotypic state y(x) (i.e., at each position x in the tumour,
the equilibrium phenotypic distribution is unimodal). Given the phenotypic state y(x), the
following conditions are simultaneously satisfied
R
(
y(x), ρ(x), s(x), c(x)
)
= max
y∈[0,1]
R
(
y, ρ(x), s(x), c(x)
)
= 0
and
∂R
∂y
(
y(x), ρ(x), s(x), c(x)
)
= 0.
9Together, the above considerations allow us to conclude that, given s(x) and c(x), there exists
a unique pair (ρ(x), y(x)) which solves the following system of equations

R
(
y(x), ρ(x), s(x), c(x)
)
= 0,
∂R
∂y
(
y(x), ρ(x), s(x), c(x)
)
= 0.
(12)
For every position x ∈ Ω, the pair (ρ(x), y(x)) characterises the local cell density and the
dominant phenotypic state at equilibrium. The formal arguments presented above are consistent
with the asymptotic analysis recently developed by Mirrahimi and Perthame for a system of
equations modelling selection dynamics in a population structured by a phenotypic trait and a
1D spatial variable [44].
Solving the system given by (12) we obtain
ρ(x) =
1
d
As(x)−Ac(x) +
(
ζ +Ac(x)
)2
ζ +As(x) +Ac(x)
 (13)
and
y(x) =
ζ +Ac(x)
ζ +As(x) +Ac(x)
, (14)
where
As(x) = γs
s(x)
αs + s(x)
and Ac(x) = γc
c(x)
αc + c(x)
.
Here, (13) and (14) demonstrate that the local cell density ρ and the phenotypic state y which
maximises the cellular fitness at position x are determined by the concentration of oxygen s and
cytotoxic drug c at the same position. This is illustrated by the heat maps in Fig. 1, which show
how, for the parameter values listed in Table 1, the values of ρ and y vary as functions of s and
c.
Together, these results suggest that local variations of abiotic factors in the tumour mi-
croenvironment determine spatial variations of selected phenotypic variants and cell densities.
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Figure 1. Plot of the local cell density ρ and the dominant phenotypic state y at equilibrium as functions of
the local concentration of oxygen s and cytotoxic drug c. The quantities ρ, s and c are scaled by the reference
values ρ0, s0 and c0 given in Table 1.
Specifically, lower values of the oxygen concentration s and higher values of the drug concen-
tration c correspond to higher values of the phenotypic state y and lower values of the local
cell density ρ. Biologically, this means that local environments hostile to highly proliferative
cells (i.e., environments characterised by lower oxygen availability and higher concentration of
the cytotoxic agent) promote the selection of cells characterised by higher levels of expression
of the hypoxia-responsive gene, which in turn leads to smaller cell numbers. On the contrary,
higher values of s and lower values of c correspond to lower values of y and higher values of
ρ. Biologically, this means that highly proliferative cells are selected for in regions with higher
oxygen and lower drug concentration, which in turn leads to larger cell densities.
Numerical solutions
We integrate the formal results established in the previous section with numerical simulations of
the coupled system given by Eqs. (3), (9) and (10). First, we consider the case where the spatial
domain Ω is an in silico tumour spheroid. Second, we consider the case where Ω corresponds
to the three dimensional geometry of an in vivo human hepatic tumour, imaged using 3D
computerised tomography. The image data were obtained from the 3D-IRCADb-01 database
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(http://www.ircad.fr/).
For the numerical simulations, we use the parameter values from the existing literature which
are listed in Table 1. Further details of numerical simulations are provided as SI. In particular, a
complete description of the numerical methods used in this work can be found in SI Appendix C.
Primarily, we report here on results obtained under the assumption that the tumour is avascular
and the concentrations of oxygen and cytotoxic drug on the boundary ∂Ω are constant (i.e.,
S(x) = s0 and C(x) = c0 for all x ∈ ∂Ω). For the sake of completeness, we performed additional
numerical simulations both in the case where abiotic factors are non-uniformly distributed on
the boundary and in the case where blood vessels are enclosed within the tumour mass. The
results obtained are presented and discussed at the end of this section.
In silico tumour spheroid simulations
The results obtained with and without the cytotoxic drug are presented in Fig. 2, where the
local concentrations of abiotic factors, the local mean phenotypic state and the local cell density
at equilibrium are shown.
Figure 2. Plots of the local concentration of cytotoxic drug c(t,x), the local concentration of oxygen s(t,x),
the local mean cell phenotypic state µ(t,x) and the local cell density ρ(t,x) at t = 70 days [i.e., close to the
steady state of Eqs. (3), (9) and (10)] in an in silico tumour spheroid of radius 800µm. The top and bottom
rows refer to the cases when the cytotoxic drug is absent and present, respectively. For visualisation, only the
bottom half of the spheroid is shown. The quantities c, s and ρ are scaled by the reference values c0, s0 and ρ0
given in Table 1.
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The concentrations of oxygen and cytotoxic drug, when present, decrease monotonically from
the edge to the centre of the spheroid. As a consequence, in the absence of drug (vid. top row
of Fig. 2), the local cell density decays radially with maximum value on the spheroid boundary.
We observe the formation of a necrotic core, with very few living cells, surrounded by a hypoxic
region, then by a more densely populated rim with more living cells present. Biologically, our
results suggest that the outer part of the spheroid becomes colonised by highly proliferative
cells, while slow-proliferating cells with a hypoxic phenotype are selected for in the interior of
the spheroid. Accordingly, the local mean phenotypic state is a radially decreasing function
from the centre to the boundary of the spheroid.
When the cytotoxic drug is present (vid. bottom row of Fig. 2), the number of living cells
is consistently reduced throughout the whole tumour spheroid. The selective pressure exerted
by the drug drives the mean phenotypic state towards drug-resistance. Moreover, the local cell
density and the local mean phenotypic state are no longer monotonic functions of the distance
from the centre of the spheroid. In this case, the density of living cells is close to zero at both
the boundary and the core of the tumour. Therefore, most of the surviving cells are found in
a thin band in the interior of the spheroid where the local mean phenotypic state attains its
minimum.
Both with and without the cytotoxic drug, at each position x the phenotypic distribution
n(t,x, y) has a Gaussian-like profile (vid. Fig. S1 in the SI); therefore, the local mean phenotypic
state coincides with the locally dominant phenotypic state. To this end, Movie S1 in the SI
demonstrates that after a short time period of transient behaviour, the local cell density ρ(t,x)
and the local mean phenotypic state µ(t,x) converge, respectively, to the equilibrium values of
the local cell density ρ(x), given by (13), and of the dominant phenotypic state y(x), given by
(14).
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In vivo human hepatic tumour simulations
Figure 3 illustrates the computerised tomography scan of the human liver tumour which we
selected as the spatial domain Ω.
Figure 3. Computerised tomography scan of a human tumour (blue) shown in situ within the liver (red).
The maximum diameter of the tumour is approximatively 3200µm. The inset shows a magnification of the
tumour with a portion made transparent, as in Fig. 4, in order to visualise the tumour bulk.
Our numerical simulations indicate that the spatial distributions of cells, oxygen and cyto-
toxic drug as well as the spatial patterns of phenotypic selection for the hepatic tumour are
qualitatively similar to those observed in the in silico tumour spheroid (compare the results in
Fig. 3 with the results of Fig. 2, and the results of Movie S1 with the results displayed by Movie
S2 in the SI).
Effects of tumour vasculature and non-uniform boundary distributions of abi-
otic factors
The results presented in Fig. 5 and Fig. 6 show that similar conclusions apply both to the case
with tumour vasculature and to the case with non-uniform boundary distributions of abiotic fac-
tors. Specifically, when the cytotoxic drug is not present, highly proliferative cells are selected
for in the tumour areas where oxygen concentration is higher. Conversely, poorly oxygenated
regions are colonised by slow-proliferating cells which express hypoxic phenotypes. These hy-
poxic cells, characterised by lower levels of drug-sensitivity, become dominant within the tumour
upon delivery of the cytotoxic drug.
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Figure 4. Plots of the local concentration of cytotoxic drug c(t,x), the local concentration of oxygen s(t,x),
the local mean cell phenotypic state µ(t,x) and the local cell density ρ(t,x) at t = 70 days [i.e., close to the
steady state of Eqs. (3), (9) and (10)] in the human hepatic tumour of Fig. 3. The top and bottom row refer to
the cases when the cytotoxic drug is absent and present, respectively. For better visualisation, only a portion of
the tumour is shown. The quantities c, s and ρ are scaled by the reference values c0, s0 and ρ0 given in Table 1.
Figure 5. Plots of the local concentration of cytotoxic drug c(t,x), the local concentration of oxygen s(t,x),
the local mean cell phenotypic state µ(t,x) and the local cell density ρ(t,x) at t = 70 days [i.e., close to the
steady state of Eqs. (3), (9) and (10)] in a slice of the in silico tumour spheroid shown in the inset. The top
and bottom row refer to the cases when the cytotoxic drug is absent and present, respectively. The quantities c,
s and ρ are scaled by the reference values c0, s0 and ρ0 given in Table 1.
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Figure 6. Plots of the local concentration of cytotoxic drug c(t,x), the local concentration of oxygen s(t,x),
the local mean cell phenotypic state µ(t,x) and the local cell density ρ(t,x) at t = 70 days [i.e., close to the
steady state of Eqs. (3), (9) and (10)] in the human hepatic tumour of Fig. 3. These results have been obtained
in the case of spatially varying boundary conditions for the abiotic factors. The top and bottom row displays
the results obtained in the absence and in the presence of cytotoxic drug, respectively. For better visualisation,
only the bottom half of the tumour is shown. The quantities c, s and ρ are scaled by the reference values c0, s0
and ρ0 given in Table 1.
Discussion
Our analysis and numerical simulations support the hypothesis that spatial variations in oxygen
levels can foster the emergence of phenotypic heterogeneity by promoting the creation of distinct
local niches within the same tumour. Our model predicts that well-oxygenated regions of the
tumour – such as the tumour periphery and areas close to blood vessels – will be densely
populated by highly proliferative cancer cells characterised by higher oxygen uptake. Conversely,
hypoxic cells with lower proliferation rates colonise tumour regions hostile to fast-proliferating
cells – such as the inner regions of the tumour where oxygen concentration is lower.
Our modelling framework offers a plausible theoretical basis for recent experimental re-
sults suggesting that the periphery and the centre of solid tumours represent distinct ecological
niches [27, 31, 45–47]. Furthermore, our findings agree with observations made in mathematical
modelling and experimental studies [31,48–51] which suggest that hypoxia favours the selection
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for cancer cells resistant to cytotoxic therapy prior to treatment. Consequently, this facilitates
the development of resistance following drug exposure.
Our analysis and numerical simulations also address the open question of how phenotypic
heterogeneity in a solid tumour changes under cytotoxic therapy. Our results complement those
of Robertson-Tessi et al. [52] by demonstrating that cytotoxic agents decrease the number of
living cancer cells and select for more resistant phenotypic variants throughout the whole tumour.
In particular, since cytotoxic drugs kill more proliferative cells in regions of the tumour with
higher oxygen concentration, the drug exposure removes the selective barrier limiting the growth
of less proliferative and more resistant cells. This reduces drug efficacy, and ultimately leads to
poor treatment outcomes and low patient survival rates [53–55].
In summary, our mathematical study highlights the role that the spatial distribution of
abiotic components in the tumour microenvironment play in mediating phenotypic heterogeneity
in solid tumours. Our results strongly support the need for spatial data when performing
phenotypic profiling of solid tumours, as single tumour biopsies are unlikely to fully represent
the complete phenotypic landscape of the tumour [4–7,56].
Histological analyses indicate that solid tumours contain cancer cells with a wide spectrum
of gene expression. However, our theoretical work provides support for the ideas proposed by
Alfarouk et al. [14], who have noted that the phenotypes of cancer cells result, to an extent,
from predictable spatial gradients in the concentrations of abiotic factors which can be mapped
out via non-invasive imaging techniques [57]. This may open up new avenues of research for
exploiting ecological principles to design innovative therapeutic protocols according to adaptive
therapy [58,59].
Additional strengths of the present study are that the parameter values used to perform
numerical simulations come from existing literature, and the outcomes of our formal analysis
are characterised by broad structural stability under parameter changes. Our framework can
accommodate parameter values for any solid tumour and the method we have used to construct
numerical solutions of the model is applicable to arbitrary geometries. Therefore, while we
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performed numerical simulations on the geometry of a given in vivo human hepatic tumour as
an illustrative example, our in silico approach can be applied to studying phenotypic selection
between cancer cells in a wide range of neoplasms.
Finally, while we have assumed multiple phenotypic variants to be present in the tumour from
the beginning of simulations and we have considered the tumour size to remain constant over
time, the modelling framework presented here can be extended to incorporate mutations and
epimutations [20, 21] as well as growing tumour spatial domains [60–64]. Given the robustness
and structural stability of our results, we expect the main conclusions of this work to hold even
after the inclusion of these additional layers of biological complexity.
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